Slide-mounted FFPE tumor samples were obtained from patients with activating PIK3CA mutations in their ER+ or HER+ breast or gynecological cancers, respectively, prior to treatment in a multicenter phase I clinical trial of capivasertib (NCT01226316). Here, PIK3CA is linked to female reproductive organ cancer.